Advertisement
Advertisement
U.S. Markets close in 5 hrs 33 mins
Advertisement
Advertisement
Advertisement
Advertisement

BioCardia, Inc. (BCDA)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.6897-0.0503 (-2.89%)
As of 09:47AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.7400
Open1.7300
Bid1.7000 x 900
Ask1.8100 x 1100
Day's Range1.6897 - 1.6897
52 Week Range1.6500 - 5.4800
Volume2,388
Avg. Volume150,585
Market Cap28.507M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-0.7610
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.63
  • GlobeNewswire

    BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference

    SUNNYVALE, Calif. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and respiratory diseases, today announced it will be delivering virtual presentations during two investor meetings: The H.C. Wainwright BioConnect Virtual Conference taking place on January 10-13The Biotech Showcase taking place January 10-12 Dr. Peter Altman and Mr. David McClung, CEO and CFO of BioCardi

  • GlobeNewswire

    BioCardia Establishes New Manufacturing Facility to Enable Its Cell Therapy Product Candidates

    Facility Being Built Out to Support CardiAMP Cell Therapy Systems, Allogeneic NK1R+ MSC and Biotherapeutic Delivery Device Manufacturing for Clinical Trials of Multiple Programs and Early Commercial ActivitiesSAN CARLOS, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that it has entered into a long-term lease for a new facility in Sunnyvale,

  • GlobeNewswire

    BioCardia Reports Third Quarter 2021 Financial Results and Business Highlights

    SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2021 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2021 with the Securities and Exchange Commission. Q3 and Recent Business Highlights: CardiAMP® Cell Therapy for ischemic heart failure (BCDA-01

Advertisement
Advertisement